trending Market Intelligence /marketintelligence/en/news-insights/trending/aVSkFcxV1zKrwpqh4KTBiw2 content esgSubNav
In This List

Lilly's Verzenio fails phase 3 trial in non-small cell lung cancer

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector


Lilly's Verzenio fails phase 3 trial in non-small cell lung cancer

Eli Lilly and Co. said the phase 3 trial of Verzenio as a monotherapy in KRAS-mutated, advanced non-small lung cancer failed to meet its main goal.

Results from the JUNIPER study showed that Verzenio was not superior to Roche Holding AG and Astellas Pharma Inc.'s Tarceva, or erlotinib, and did not meet the end goal for overall survival.

However, an analysis of the secondary study endpoints of both progression-free survival and overall response rate showed evidence of monotherapy activity in the Verzenio arm of the study.

The U.S. Food and Drug Administration approved Verzenio, or abemaciclib, in September to treat advanced or metastatic breast cancer that has progressed following endocrine therapy.